Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood components

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    447 result(s) found for: Blood components. Displaying page 1 of 23.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-001864-50 Sponsor Protocol Number: IIV-268 Start Date*: 2013-07-22
    Sponsor Name:National Institute for Public Health and the Environment (RIVM, the Netherlands)
    Full Title: Long-term memory immunity against Bordetella pertussis in children 9 years of age who have been vaccinated with acellular pertussis vaccines: effect of an extra preadolescent acellular booster vacc...
    Medical condition: The vaccine administered in this study is used to prevent pertussis caused by the bacterium Bordetella pertussis
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004561-34 Sponsor Protocol Number: 4.2006.1285 Start Date*: 2006-11-16
    Sponsor Name:St. Olavs Hospital
    Full Title: Tranexamic acid to elderly patients undergoing combined AVR and CABG surgery.
    Medical condition: We will investigate whether tranexamic acid given as a bolus injection at the start of surgery followed by a continuous infusion during surgery reduces postoperative bleeding in patients above 70 y...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006253-29 Sponsor Protocol Number: CLI00070 Start Date*: 2012-07-31
    Sponsor Name:Cerus Corporation
    Full Title: A Randomized Controlled Double-Blind Phase 3 Study to Assess Characteristics of S-303 Treated RBC Components and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia
    Medical condition: Acute anemia secondary to cardiovascular surgery.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10054312 Anemia postoperative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002567-42 Sponsor Protocol Number: 5A Start Date*: 2015-07-15
    Sponsor Name:Stockholm County Council, Karolinska University Hospital Huddinge, Dept of Anesthesiology and Intensive Care
    Full Title: Predictors of albumin synthesis rate in severe liver failure. An open exploratory study in patients with chronic liver failure assessed for liver transplantation
    Medical condition: Severe chronic liver failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000130-18 Sponsor Protocol Number: 1 Start Date*: 2020-10-09
    Sponsor Name:Fundación para la Inv. Biomédica Hospital Clínico San Carlos
    Full Title: Co-THEIA (Combination THerapy with mEthotrexate and adalImumAb for uveitis): Efficacy, safety and cost-effectiveness of methotrexate, adalimumab, or their combination in non infectious non anterior...
    Medical condition: Non infectious non anterior uveitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000250-55 Sponsor Protocol Number: RASQAL Start Date*: 2012-07-12
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für innere Medizin III
    Full Title: Renin-Angiotensin System Quantification in patients treated with Aliskiren or Candesartan (RASQAL)
    Medical condition: - Chronic kidney disease stages III-IV (defined by MDRD formula) - Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002175-34 Sponsor Protocol Number: EPOCH Start Date*: 2012-10-23
    Sponsor Name:Med. Univ. Wien, Universitätsklinik f. Innere Medizin III, Abt. f. Nephrologie und Dialyse
    Full Title: Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients with Hypertension (EPOCH)
    Medical condition: proteinuric patients suffering from chronic kidney disease (II - III) ,diabetes mellitus II and hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000039-73 Sponsor Protocol Number: CSPP100A2327 Start Date*: 2005-07-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An 8-week randomized, double-blind, parallel group, multi-center, placebo and active controlled dose escalation study to evaluate the efficacy and safety of aliskiren (150 mg and 300 mg) administer...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-004550-15 Sponsor Protocol Number: 64179375THR2001 Start Date*: 2017-10-11
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design Dose-Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Vers...
    Medical condition: Thromboembolism in subjects who have undergone an elective primary unilateral total knee replacement
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) PL (Completed) LV (Completed) LT (Prematurely Ended) BG (Completed) GR (Completed) PT (Completed) IT (Completed) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001298-30 Sponsor Protocol Number: NL81102.100.22 Start Date*: 2022-07-28
    Sponsor Name:St. Antonius Hospital
    Full Title: What is the optimal antithrombotic strategy in patients with atrial fibrillation having acute coronary syndrome or undergoing percutaneous coronary intervention?
    Medical condition: Atrial fibrillation and coronary artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004805-28 Sponsor Protocol Number: NL71116.100.19 Start Date*: 2020-03-10
    Sponsor Name:St. Antonius Hospital
    Full Title: What is the optimal antithrombotic strategy in patients presenting with acute coronary syndrome having atrial fibrillation with indication for anticoagulants?
    Medical condition: Acute coronary syndrome in patients with known or new atrial fibrillation with indication for oral anticoagulants
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002252-33 Sponsor Protocol Number: CSPP100A2304 Start Date*: 2005-01-28
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in p...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003896-24 Sponsor Protocol Number: D169AC00001 Start Date*: 2017-01-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease
    Medical condition: Chronic kidney disease (CKD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) DK (Prematurely Ended) ES (Completed) DE (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002150-12 Sponsor Protocol Number: DANSVIGT Start Date*: 2017-10-11
    Sponsor Name:Danish Society of Cardiology, Heart Failure Working Group
    Full Title: DanHeart (H-HeFT / Met-HeFT)
    Medical condition: Heart Failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002920-33 Sponsor Protocol Number: CLI00076 Start Date*: 2012-12-10
    Sponsor Name:CERUS CORPORATION
    Full Title: A Randomized Controlled Study to Evaluate Efficacy and Safety of S-303 Treated Red Blood Cells in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion
    Medical condition: Subjects with Thalassemia Major Requiring Chronic RBC Transfusion
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003897-41 Sponsor Protocol Number: D1699C00001 Start Date*: 2017-01-19
    Sponsor Name:AstraZeneca AB
    Full Title: Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction
    Medical condition: Chronic Heart Failure (HF) with Reduced Ejection Fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) DE (Completed) DK (Completed) BG (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-003963-30 Sponsor Protocol Number: D2456C00002 Start Date*: 2007-02-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil 32 mg and Hydro...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9 10020772 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) SK (Completed) HU (Completed) BE (Completed) MT (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003368-64 Sponsor Protocol Number: CS-BM32-002 Start Date*: 2011-10-12
    Sponsor Name:Biomay AG
    Full Title: Safety and dose finding study based on the effects of three subcutaneous injections of BM32, a recombinant hypoallergenic grass pollen vaccine, on responses to allergen challenge by skin testing an...
    Medical condition: Grass pollen allergy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000334-17 Sponsor Protocol Number: TRACK_001 Start Date*: 2023-03-31
    Sponsor Name:The George Institute of Global Health
    Full Title: Treatment of cardiovascular disease with low Rivaroxaban in Advanced Chronic Kidney Disease - TRACK trial
    Medical condition: Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000517-33 Sponsor Protocol Number: RP-L201-0318 Start Date*: 2020-07-14
    Sponsor Name:Rocket Pharmaceuticals, Inc.
    Full Title: Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I):A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Len...
    Medical condition: Leukocyte Adhesion Deficiency-I (LAD-I)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018137 Genetic anomalies of leukocytes LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 22:25:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA